Page 1

Exhibit 99.1 Eton Pharmaceuticals Reports Third Quarter Financial Results DEER PARK , Ill . , Nov. 15 , 2021 ( GLOBE NEWSWIRE ) · Eton Pharmaceuticals , Inc ( Nasdaq : ETON ) , an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases , today reported financial results for the third quarter ended September 30 , 2021 . " Over the last month we have made tremendous advancements to our commercial portfolio . We gained two more FDA - approved products , EPRONTIA and carglumic acid , both of which should launch in the fourth quarter , and we are increasing ALKINDI SPRINKLE's commercial footprint more than ten - fold through an attractive co - promotion arrangement with Tolmar Pharmaceuticals . These events put us in an even stronger position to deliver significant revenue and reach sustained profitability in 2022 , ” said Sean Brynjelsen , CEO of Eton Pharmaceuticals . Major Business Updates Acquired marketing rights to FDA - approved carglumic acid tablets . Eton's product is the first and only generic alternative to Carbaglu® and is indicated for acute and chronic hyperammonemia due to N - acetylglutamine Synthase ( NAGS ) deficiency . Carbaglu® is widely believed to be one of the most expensive treatments in the world and Eton looks forward to offering a lower - cost alternative to patients and caregivers . TM FDA Approval of EPRONTIA ™ ( topiramate ) oral solution . Earlier this month , the U.S. Food and Drug Administration ( FDA ) approved EPRONTIA ™ , the first oral liquid formulation of topiramate . EPRONTIA ™ is now Eton's sixth approved product . The product will be launched by Azurity Pharmaceuticals and is expected to be available before the end of the year . The product's launch will trigger a $ 5 million milestone payment to Eton , and Eton will also receive a royalty on sales of the product and potential future commercial milestone payments . Significantly expanded ALKINDI SPRINKLEⓇ'S commercial footprint through a co - promotion partnership with Tolmar Pharmaceuticals . Tolmar's 62 - person commercial sales force is expected to be fully trained and promoting ALKINDI SPRINKLEⓇ in December . The transaction is expected to significantly accelerate product adoption and ALKINDI SPRINKLEⓇ sales growth . ALKINDI SPRINKLEⓇ Commercial Update In a separate press release issued this morning , Eton announced that it has entered into a co - promotion arrangement with Tolmar Pharmaceuticals for the promotion of ALKINDI SPRINKLEⓇ . ALKINDI SPRINKLE® sales continued to grow month - over - month in the third quarter and in October . During the quarter , Eton held an advisory panel with key opinion leaders in the pediatric endocrinology community and product feedback continues to be overwhelmingly positive as doctors appreciate the critical importance of precisely dosing pediatric patients when treating adrenal insufficiency . Eton believes in - person meetings have proven to be effective at driving adoption , and as a result , is drastically increasing ALKINDI SPRINKLEⓇ's commercial footprint through the co - promotion arrangement .